31/07/2026

Dear Healthcare Professional,

Supply update of PEGASYS® peginterferon alfa-2a 135 micrograms/0.5 mL injection pre-filled syringe (AUST R: 91836) and PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (AUST R: 91837)

Echo Therapeutics, the supplier of PEGASYS® peginterferon alfa-2a 135 mcg (AUST R: 91836) and 180 mcg (AUST R: 91837) wishes to update you on the following:

1. **PEGASYS® peginterferon alfa-2a 135 mcg (AUST R: 91836)**

- Supply of the Australian labelled product has resumed.
- Supply remains constrained due to global pipeline filling. Therefore, the patient supply pathway will continue via Just Meds (home delivery partner) until ongoing supply returns to pre-shortage volumes.
- Hospitals will continue to order from Symbion and Queensland Health (for Queensland Public Hospitals) until ongoing supply returns to pre-shortage volumes.
- Please advise patients that, for a short period, they may receive either Irish labelled product, or the newly available Australian labelled product until stock of the Irish labelled product is exhausted at Symbion, Just Meds or the hospital.

2. **PEGASYS® peginterferon alfa-2a 180 mcg (AUST R: 91837)**

- This product remains under shortage, and the alternate supply of the previously approved PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (Ireland) will continue.
- This product is NOT registered in Australia, and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under Section 19A of the *Therapeutic Goods Act 1989* until 31 July 2026 for the following indications:

Chronic Hepatitis C (CHC)

The combination of Pegasys and ribavirin is indicated for the treatment of chronic hepatitis C in patients who have received no prior interferon therapy (treatment-naïve patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin.

The combination of Pegasys and ribavirin is also indicated for the treatment of chronic hepatitis C patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy.

Pegasys monotherapy is indicated for the treatment of chronic hepatitis C in treatment-naïve patients. Patients must be 18 years of age or older and have compensated liver disease.

Chronic Hepatitis B (CHB)

PEGASYS is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.

- PEGASYS® peginterferon alfa-2a180 micrograms/0.5 mL injection pre-filled syringe (Ireland) is registered and marketed in Ireland and therefore the labelling, although similar, is not identical. The approved Section 19A products and the Australian product are identical in active ingredient, strength, and formulation.
- Patients should be advised to disregard the CMI/patient leaflet for PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (Ireland) contained within the pack and refer to the Australian Consumer Medicines Information available from the Echo Therapeutics' website.

Please refer to the Australian Product Information for PEGASYS® peginterferon alfa-2a 135 micrograms/0.5 mL injection pre-filled syringe (AUST R: 91836) and PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (AUST R: 91837) available at https://www.ebs.tga.gov.au when prescribing PEGASYS® peginterferon alfa-2a 135 micrograms/0.5 mL injection pre-filled syringe or PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (Ireland).

Adverse Event Reporting

Reporting any suspected adverse event is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with PEGASYS® peginterferon alfa-2a 135 micrograms/0.5 mL injection pre-filled syringe or PEGASYS® peginterferon alfa-2a 180 micrograms/0.5 mL injection pre-filled syringe (Ireland) should be reported by healthcare professionals and patients to Echo Therapeutics on 1300 848 328 or by email drugsafety@echotherapeutics.net. Alternatively, this information can be reported directly to the TGA.

Please forward this information to relevant staff members in your organisation.

For additional information, please contact Echo Therapeutics on 1300 848 328 or email customerservice@echotherapeutics.net.

Yours sincerely,

Jude D'Silva
Managing Director
Echo Therapeutics Pty Ltd